[Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
30 patients with renal tumours were treated with Depo-Provera (Medroxyprogesterone). Among the 21 patients operated on without metastases and with an parallel metastasis (fibrous capsule, adipose capsule, peritoneum) in the course of 6 to 15 months no one died of a tumour progression. Among the 9 patients with a distant metastasis in one case the regression of the metastasis could be achieved, whereas in another case progesterone stopped the progression of the intraoperatively observed liver metastasis.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004621:Embolization, Therapeutic; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D009362:Neoplasm Metastasis
D000970:Antineoplastic Agents; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone
Erfahrungen mit Depo-Provera (Medroxyprogesteron) bei der Behandlung von Nierentumoren.